Pembrolizumab is now approved by the FDA and the EMA for the treatment of locally recurrent unresectable or metastatic TNBC in adults whose tumours express PD-L1 with a combined positive score (CPS) ≥ 10, and who have not received prior chemotherapy for metastatic disease. Here, CD274 is linked to neoplasm.